Abstract Library

#2916 Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus?

Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wetz C, Genseke P, Schatka I, Jann H, Rogasch J,

Keywords: Neuroendocrine Neoplasia, Asphericity, Everolimus, Prediction,

#2188 Predictive Markers of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)

Introduction: NET are relatively rare and up to still far from fully studied pathology. The frequency of NET GEP does not exceed 2% of all tumors of this localization.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Issaeva S, Khalimova Z, Safarova M, Gumarova A, Yuldashev A,

Keywords: gastroenteropancreatic neuroendocrine tumors, morphology, clinical,

#2143 Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams

Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Xu J

Authors: Jia R, Li Y, Jin Y, Chen Y, Zhang Y,

Keywords: NEC, checkpoint blockade, anti-PD-1 antibody, NENs,

#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors

Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Daskalakis K

Authors: Daskalakis K, Norlén O, Karakatsanis A, Hellman P, Larsson R,

Keywords: Ex vivo activity, Cytotoxic drugs, Targeted agents, small intestinal neuroendocrine tumors,

#1524 Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs)

Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lock A

Authors: Lock A, Wirtz R, Kaemmerer D, Haugvik S, Kure E,

Keywords: PREDICT-Study, everolimus, pNEN, gene signature, predictive marker,